http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ji, Eunhee,Kim, Mi-young,Yun, Hwi-yeol,Kim, Kyung Im,Kang, Wonku,Kwon, Kwang-il,Kim, In-Wha,Lee, Hye Suk,Shin, Wan Gyoon,Oh, Jung Mi Pharmacotherapy Publications, Inc 2011 Pharmacotherapy Vol.31 No.6
<P>To estimate the population pharmacokinetic parameters of cyclosporine in Korean adults undergoing living-donor kidney transplantation, and to identify clinical factors affecting cyclosporine pharmacokinetics.</P>
Ji, Eunhee,Choi, Leena,Suh, Kyung-Suk,Cho, Joo-Youn,Han, Nayoung,Oh, Jung Mi Lippincott Williams Wilkins, Inc. 2012 Transplantation Vol.94 No.8
BACKGROUND: For living donor liver transplantation, the genetic association of CYP3A5 genotype of recipient’s native intestine and donor’s liver allograft with tacrolimus pharmacokinetics has not been explained completely considering liver regeneration time. The goal of the study was to investigate the longitudinal effects of recipient-donor combinational CYP3A5 genotypes on tacrolimus dose-normalized concentration (C/D ratio) in blood. METHODS: Tacrolimus blood concentrations were measured for 58 Korean adult living donor liver transplant recipients on tacrolimus-based immunosuppressants during 4 years of follow-up. CYP3A5 was genotyped for both recipient and donor, and the recipient-donor combinational genetic effect on tacrolimus C/D ratios were evaluated as a function of time after adjusting for covariates including demographics and clinical variables. RESULTS: CYP3A5 expresser recipients grafted from CYP3A5 expresser donors consistently had the least C/D ratio throughout the entire study period, whereas CYP3A5 expresser recipients grafted from CYP3A5 nonexpresser donors had an intermediate, and CYP3A5 nonexpresser recipients grafted from CYP3A5 nonexpresser donors had the largest C/D ratio (all P < 0.01). The CYP3A5 nonexpresser recipients grafted from CYP3A5 expresser donors showed a significant decrease from the largest to the intermediate in C/D ratio for the first month. CONCLUSIONS: CYP3A5 genotypes of both recipient and donor were important factors influencing pharmacokinetic variability of tacrolimus. The recipient-donor combinational genetic effect on C/D ratio changed over time after transplantation.
식품의약품안전청의 의약품안전사용정보방 웹사이트 구축을 위한 컨텐츠 개발
지은희(Eunhee Ji),박효영(Hyo Yung Park),노혜진(Hyejin Noh),이동은(Dong Eun Lee),한나영(Nayoung Han),정소현(Sohyun Jeong),김인화(In-Wha Kim),신완균(Wan Gyoon Shin),오정미(Jung Mi Oh) 대한약학회 2012 약학회지 Vol.56 No.3
The purpose of this study was to construct database for a drug safety information website to serve as an access point of up-to-date resources for a wide variety of drug-safety information helping patients and healthcare professionals make well-informed decisions about medication use. All the contents developed were confirmed by the council of advisors who were the experts in drug safety. The detailed contents of database on frequently prescribed drug including 9 NSAIDs, 19 antibiotics, 24 cardiovascular, 21 metabolic, 14 respiratory, 20 digestive, 22 hormonal, 10 genitourinary, 10 anti-allergic, 27 antifungal/antiviral, and 71 neuropsychiatric agents were developed based on the approved drug labeling of the Korean FDA. A separately searchable database of drug-specific safety information for patients and health professionals was constructed for users in need of different depth of knowledge on using medications safely. The safety information on highly prevalent chronic diseases and drug classes was also developed. Finally the most recent global drug safety news was provided. The consumer directed information was developed in layman’s terms as means of proving user-friendly information. The creation of this type of website is part of the Korean FDA’s ongoing initiative to address and promote the safe use of medications for the public.
Discriminating Schizotypy using EEG during Audiovisual Emotion Perception Test
( Eunhee Chang ),( Ji Woon Jeong ),( Tariku W. Wendimagegn ),( Yesul Chun ),( Hyoung Joong Kim ),( Hyun Taek Kim ) 한국감성과학회 2015 추계학술대회 Vol.2015 No.-
Schizotypy refers to the personality trait of experiencing ‘psychotic’ symptoms and can be regarded as a predisposition of schizophrenia-spectrum psychopathology. One of the common symptoms associated with schizophrenia is deficits in emotional perception while schizotypal individuals show inconsistent results. In the present study, we investigated facial emotion recognition in schizotypy and implemented the machine learning technique to find out whether the schizotypy group is distinguishable from the control group using EEG signals. Fifty-one subjects participated and were divided into two groups (Schizotypy: N = 34, Control: N = 17) according to the Schizotypal Personality Questionnaire (SPQ) score. All participants performed audiovisual emotion perception test (AEPT) during the EEG recording. Shrinkage Linear Discriminant Analysis (SKLDA) revealed that brain activities of the total participants were clearly separated into two groups and the accuracy of the classification was above 94%. This result implies that the underlying process of emotion recognition in schizotypy may differ from that of the control group at the neural level.
BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis
Choi, Eunhee,Choe, Hyerim,Min, Jaewon,Choi, Ji Yoon,Kim, Jimi,Lee, Hyunsook Nature Publishing Group 2009 The EMBO journal Vol.28 No.14
<P>Regulation of BubR1 is central to the control of APC/C activity. We have found that BubR1 forms a complex with PCAF and is acetylated at lysine 250. Using mass spectrometry and acetylated BubR1-specific antibodies, we have confirmed that BubR1 acetylation occurs at prometaphase. Importantly, BubR1 acetylation was required for checkpoint function, through the inhibition of ubiquitin-dependent BubR1 degradation. BubR1 degradation began before the onset of anaphase. It was noted that the pre-anaphase degradation was regulated by BubR1 acetylation. Degradation of an acetylation-mimetic form, BubR1–K250Q, was inhibited and chromosome segregation in cells expressing BubR1–K250Q was markedly delayed. By contrast, the acetylation-deficient mutant, BubR1–K250R, was unstable, and mitosis was accelerated in BubR1–K250R-expressing cells. Furthermore, we found that APC/C–Cdc20 was responsible for BubR1 degradation during mitosis. On the basis of our collective results, we propose that the acetylation status of BubR1 is a molecular switch that converts BubR1 from an inhibitor to a substrate of the APC/C complex, thus providing an efficient way to modulate APC/C activity and mitotic timing.</P>